Aquestive Therapeutics Inc
NASDAQ:AQST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aquestive Therapeutics Inc
Cash from Financing Activities
Aquestive Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Cash from Financing Activities
$102.6m
|
CAGR 3-Years
107%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Aquestive Therapeutics Inc
Glance View
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.
See Also
What is Aquestive Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
102.6m
USD
Based on the financial report for Dec 31, 2025, Aquestive Therapeutics Inc's Cash from Financing Activities amounts to 102.6m USD.
What is Aquestive Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
29%
Over the last year, the Cash from Financing Activities growth was 23%. The average annual Cash from Financing Activities growth rates for Aquestive Therapeutics Inc have been 107% over the past three years , 29% over the past five years .
